Adverum Biotechnologies, Inc. (NASDAQ:ADVM) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call July 17, 2024 8:00 AM ET Company Participants Mike Zanoni - Head of IR Laurent Fischer - President & CEO Charles Wykoff - Director of Research, Retina Consultants of Texas Conference Call Participants Joon Lee - Truist Securities Joseph Thome - TD Cowen Francois Brisebois - Oppenheimer Graig Suvannavejh - Mizuho Securities Luca Issi - RBC Capital Daniil Gataulin - Chardan Operator Hello, ladies and gen ...

-   6E10 combined with local prophylaxis selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks -   Efficacy: 76% of 6E10 patients were injection free, with maintained visual acuity and fluid control -   Safety: 100% of 6E10 difluprednate-alone patients had no or minimal inflammation, and none received corticosteroids for treatment of inflammation beyond the scheduled prophylaxis -   Patient Preference Survey: 88% of patients indicated a ...

Adverum Biotechnologies (ADVM) closed the last trading session at $8.67, gaining 18.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.86 indicates a 290.5% upside potential.The average comprises seven short-term price targets ranging from a low of $20 to a high of $60, with a standard deviation of $14.05. While the lowest estimate indicates an increase of 130.7% from the curre ...

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retin ...

REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointments of Dr. Rabia Gurses Ozden to the Company's executive leadership team as chief medical officer and Dr. Szilárd Kiss to the Company's Board of Directors. Dr. Ozden has stepped down from the Company's Board of Directors, with Dr. Kiss filling the existing B ...

Adverum Biotechnologies (ADVM) has been on a downward spiral lately with significant selling pressure. After declining 19.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whet ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________________________________________________ FORM 10-Q ___________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to Com ...

Exhibit 99.1 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 - REDWOOD CITY, Calif., May 9, 2024 - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standar ...

REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright 2nd Annual B ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Adverum Biotechnologies (ADVM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Adverum Biotechnologies is one of 1051 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different g ...